Propanc Biopharma, Inc. (PPCB) Form 10-K — Sep 25, 2026
Propanc Biopharma filed its fiscal 2026 10-K with a going-concern warning: the company held just $832,006 in cash at June 30, 2026 against $5.68 million of annual operating cash burn and states it does not have enough cash to meet obligations over the next 12 months. Net loss narrowed to $18.86 million from $58.92 million the prior year, driven mainly by a roughly $39 million drop in non-cash stock-based compensation and consulting expenses. The company is pre-revenue, with only two full-time employees.
Key figures
- Revenue
- 0
- Total Assets
- 12799912
- Cash Position
- 832006
- Record holders
- 103
- Last sale price
- $0.62 (Sept 18, 2026)
- Current liabilities
- 3354433
- Net loss prior year
- 58923300
- Phase ib estimated cost
- $6.5 million
- Granted or allowed patents
- 85
- Market value non affiliates
- 2655995
- Shares outstanding sept 2026
- 6331116
- Net cash provided by financing
- 6457298
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.